Beside Cetuximab, other ErbB-targeting agents are being evaluated in combination with ICIs for HNSCC, including the anti-ErbB2 antibodies Margetuximab, BDC-1001 and SBT6050, and the EGFR/ErbB2/ErbB4 inhibitor Afatinib (Table 2). This evidence concerns the gene ERBB4 and head and neck squamous cell carcinoma.